Evidence map›Paper›PMID 40426240›Full record

ArticleVirology journal2025

Integrated in-silico design and in vivo validation of multi-epitope vaccines for norovirus.

Jingxuan Qiu, Yiwen Wei, Jiayi Shu, Wenjing Zheng, Yuxi Zhang, Junting Xie, Dong Zhang, Xiaochuan Luo, Xiulan Sun, Xin Wang and 3 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Virology journal, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Jingxuan Qiu *School of Health Science and Engineering, University of Shanghai for Science and Technology, Shanghai, 200093, China.
Yiwen Wei *School of Health Science and Engineering, University of Shanghai for Science and Technology, Shanghai, 200093, China.
Jiayi Shu *Institute of Clinical Science, Clinical Center of Biotherapy, Zhongshan Hospital, Shanghai Institute of Infectious Disease and Biosecurity, Intelligent Medicine Institute, Shanghai Medical College, Fudan University, 200032, Shanghai, China.
Wenjing ZhengInstitutes of Biomedical Sciences; Shanghai Institute of Infectious Disease and Biosecurity, Key Laboratory of Medical. Molecular Virology of MoE&MoH, Shanghai Medical College, Fudan University, 200032, Shanghai, China.
Yuxi ZhangSchool of Health Science and Engineering, University of Shanghai for Science and Technology, Shanghai, 200093, China.
Junting XieSchool of Health Science and Engineering, University of Shanghai for Science and Technology, Shanghai, 200093, China.
Dong ZhangSchool of Health Science and Engineering, University of Shanghai for Science and Technology, Shanghai, 200093, China.
Xiaochuan LuoSchool of Health Science and Engineering, University of Shanghai for Science and Technology, Shanghai, 200093, China.
Xiulan SunState Key Laboratory of Food Science and Technology, School of Food Science and Technology, National Engineering Research Center for Functional Foods, Synergetic Innovation Center of Food Safety and Nutrition, Jiangnan University, Wuxi, Jiangsu,, 214122, China.
Xin WangSchool of Health Science and Engineering, University of Shanghai for Science and Technology, Shanghai, 200093, China.
Sijie WangInstitutes of Biomedical Sciences; Shanghai Institute of Infectious Disease and Biosecurity, Key Laboratory of Medical. Molecular Virology of MoE&MoH, Shanghai Medical College, Fudan University, 200032, Shanghai, China. sijieW@outlook.com.
Xuanyi WangInstitutes of Biomedical Sciences; Shanghai Institute of Infectious Disease and Biosecurity, Key Laboratory of Medical. Molecular Virology of MoE&MoH, Shanghai Medical College, Fudan University, 200032, Shanghai, China. xywang@shmu.edu.cn.
Tianyi QiuInstitute of Clinical Science, Clinical Center of Biotherapy, Zhongshan Hospital, Shanghai Institute of Infectious Disease and Biosecurity, Intelligent Medicine Institute, Shanghai Medical College, Fudan University, 200032, Shanghai, China. qiu.tianyi@zs-hospital.sh.cn.

Funding

National Key Research and Development Program of China 2022YFF1101104National Natural Science Foundation of China 32370697
6 · The paper itself

Abstract

backgroundNorovirus (NoVs) is a foodborne pathogen that causes acute gastroenteritis. The diversity of its principal antigenic protein poses a significant challenge to vaccine development and the prevention of large-scale outbreaks globally. Currently, no licensed vaccines against norovirus have been approved.

methodsWe developed a novel pipeline that integrates multiple bioinformatics tools to design broad-spectrum vaccines against NoVs. Specifically, broad-spectrum T-cell epitope vaccines were designed based on consensus sequences and optimized epitope screening, while broad-spectrum B-cell spatial epitope vaccines were constructed using high-throughput antigenicity calculations and epitope mapping.

resultsThis pipeline underwent rigorous validation at three levels: firstly, In silico validation: Analysis of properties and structures demonstrated the appropriateness of amino acid composition and the structural integrity of the vaccine sequences. Secondly, theoretical assessment: Evaluation of human leukocyte antigen (HLA) subtype and antigenicity coverage indicated a broad theoretical protective spectrum for the designed vaccine immunogens. Furthermore, in silico simulation confirmed their ability to elicit an immune response. Finally, animal-level validation: Experiments in mice showed that both vaccine immunogens stimulated high levels of IgG and IgA. Notably, Vac-B induced a strong IgG response against GII.2 and a robust IgA response against GII.17, comparable to the immune response elicited by the wild-type NoV non-replicating virus-like particle (VLP) protein group.

conclusionsBoth in silico and in vivo experimental findings suggest that the proposed pipeline and vaccine immunogens could serve as valuable theoretical guidance for the development of multi-epitope vaccines against NoVs.

Indexed as

Caliciviridae InfectionsEpitopes, B-LymphocyteEpitopes, T-LymphocyteNorovirusViral VaccinesAnimalsAntibodies, ViralComputational BiologyComputer SimulationEpitope MappingFemaleGastroenteritisHumansImmunoglobulin AImmunoglobulin GMiceAntibodies, ViralEpitopes, B-LymphocyteEpitopes, T-LymphocyteImmunoglobulin AImmunoglobulin GViral VaccinesB-cell spatial epitopeBroad-spectrumMulti-epitopes vaccineNorovirusT-cell epitope

Identifiers

PMID40426240
PMCPMC12117790

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.